Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_2745_Библиотеки_им_академика_М_И_Перельмана
.pdf
Med Case Rep. 2013;7:270. doi:10.1186/1752-1947-7-270.
Petousi N, Thomas EC. Interferon-β-induced pulmonary sarcoidosis in a 30-year-
old woman treated for multiple sclerosis: a case report. J Med Case Rep.
2012;6(1):344. doi:10.1186/1752-1947-6-344.
Carbonelli C, Montepietra S, Caruso A, et al. Sarcoidosis and multiple sclerosis:
systemic toxicity associated with the use of interferon-beta therapy. Monaldi
Arch Chest Dis. 2012;77(1):29-31. doi:10.4081/monaldi.2012.165.
Viana de Andrade AC, Brito ÉA, Harris OM, Viana de Andrade AP, Leite MF,
Pithon MM. Development of systemic sarcoidosis and xanthoma planum during
multiple sclerosis treatment with interferon-beta 1a: case Report. Int J Dermatol.
2015;54(5):e140-145. doi:10.1111/ijd.12676.
Bobbio-Pallavicini E, Valsecchi C, Tacconi F, Moroni M, Porta C. Sarcoidosis
following beta-interferon therapy for multiple myeloma. Sarcoidosis.
1995;12(2):140-142.
Abdi EA, Nguyen GK, Ludwig RN, Dickout WJ. Pulmonary sarcoidosis following
interferon therapy for advanced renal cell carcinoma. Cancer. 1987;59(5):896-
900.
Navne JE, Hedegaard U, Bygum A. Activation of psoriasis in patients undergoing
treatment with interferon-beta. Ugeskr Laeger. 2005;167(32):2903-2904.
Kolb-Mäurer A, Goebeler M, Mäurer M. Cutaneous adverse events associated with
interferon-β treatment of multiple sclerosis. Int J Mol Sci. 2015;16(7):14951-
14960. doi:10.3390/ijms160714951.
La Mantia L, Capsoni F. Psoriasis during interferon beta treatment for multiple
sclerosis. Neurol Sci. 2010;31(3):337-339. doi:10.1007/s10072-009-0184-x.
López-Lerma I, Iranzo P, Herrero C. New-onset psoriasis in a patient treated with
interferon beta-1a. Br J Dermatol. 2009;160(3):716-717. doi:10.1111/j.1365-
2133.2008.09005.x.
Axtell R, Raman C, Steinman L. Interferon-β exacerbates Th17 inflammatory
diseases. Trends Immunol. 2011;32(6):272-277. doi:10.1016/j.it.2011.03.008.
Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R. Three times weekly
glatiramer acetate in relapsing–remitting multiple sclerosis. Ann Neurol.
2013;73(6):705-713. doi:10.1002/ana.23938.
Boster A, Bartoszek MP, O’Connell C, Pitt D, Racke M. Efficacy, safety, and cost-
effectiveness of glatiramer acetate in the treatment of relapsing–remitting
multiple sclerosis. Ther Adv Neurol Disord. 2011;4(5):319-332.
doi:10.1177/1756285611422108.
Teva Neuroscience. Copaxone [Package Insert]. Kansas City, MO: Teva
Neuroscience; 2009.
Aviv B, Yaron Z, Anat A, Sharon B. Patterns of local site reactions to subcutaneous
glatiramer acetate treatment of multiple sclerosis: a clinicopathological study.
Int J Clin Exp Pathol. 2018;11(6):3126-3133.
Ball NJ, Cowan BJ, Moore GRW, Hashimoto SA. Lobular panniculitis at the site of
glatiramer acetate injections for the treatment of relapsing-remitting multiple
sclerosis. A report of two cases. J Cutan Pathol. 2008;35(4):407-410.
doi:10.1111/j.1600-0560.2007.00819.x.
Sánchez-López J, Rodríguez del Rio P, Cases-Ortega B, Martínez-Cócera C,
Fernández-Rivas M. Allergy workup in immediate-type local reactions to
https://t.me/medicina_free
glatiramer acetate. J Investig Allergol Clin Immunol. 2010;20(6):521-523.
Drago F, Rongioletti F, Battifoglio ML, Rebora A. Localised lipoatrophy after
acupuncture. Lancet. 1996;347(9013):1484.
doi:10.5555/uri:pii:S0140673696917195.
Mancardi GL, Murialdo A, Drago F, et al. Localized lipoatrophy after prolonged
treatment with copolymer 1. J Neurol. 2000;247(3):220-221.
doi:10.1007/s004150050568.
Edgar CM, Brunet DG, Fenton P, McBride EV, Green P. Lipoatrophy in patients
with multiple sclerosis on glatiramer acetate. Can J Neurol Sci. 2004;31(1):58-
63.
Soós N, Shakery K, Mrowietz U. Localized panniculitis and subsequent lipoatrophy
with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of
multiple sclerosis. Am J Clin Dermatol. 2004;5(5):357-359.
Hwang L, Orengo I. Lipoatrophy associated with glatiramer acetate injections for
the treatment of multiple sclerosis. Cutis. 2001;68(4):287-288.
Jolly H, Simpson K, Bishop B, et al. Impact of warm compresses on local injection-
site reactions with self-administered glatiramer acetate. J Neurosci Nurs.
2008;40(4):232-239.
Hashimoto S, Ball N, Tremlett H. Progressive lipoatrophy after cessation of
glatiramer acetate injections: a case report. Mult Scler. 2009;15(4):521-522.
doi:10.1177/1352458508100504.
Harde V, Schwarz T. Embolia cutis medicamentosa following subcutaneous
injection of glatiramer acetate. J Dtsch Dermatol Ges. 2007;5(12):1122-1123.
doi:10.1111/j.1610-0387.2007.06391.x.
Mott SE, Peña ZG, Spain RI, White KP, Ehst BD. Nicolau syndrome and localized
panniculitis: a report of dual diagnoses with an emphasis on morphea profundalike changes following injection with glatiramer acetate. J Cutan Pathol.
2016;43(11):1056-1061. doi:10.1111/cup.12791.
McEwan L, Brown J, Poirier J, et al. Best practices in skin care for the multiple
sclerosis patient receiving injectable therapies. Int J MS Care. 2010;12(4):177-
189. doi:10.7224/1537-2073-12.4.177.
Caon C, Namey M, Meyer C, et al. Prevention and management of infusion-
associated reactions in the comparison of alemtuzumab and Rebif® efficacy in
multiple sclerosis (CARE-MS) program. Int J MS Care. 2015;17(4):191-198.
doi:10.7224/1537-2073.2014-030.
Šega-Jazbec S, Barun B, Horvat Ledinek A, Fabekovac V, Krbot Skorić M, Habek
M. Management of infusion related reactions associated with alemtuzumab in
patients with multiple sclerosis. Mult Scler Relat Disord. 2017;17:151-153.
doi:10.1016/j.msard.2017.07.019.
Thomas K, Eisele J, Rodriguez-Leal FA, Hainke U, Ziemssen T. Acute effects of
alemtuzumab infusion in patients with active relapsing-remitting MS. Neurol
Neuroimmunol Neuroinflamm. 2016;3(3):e228.
doi:10.1212/NXI.0000000000000228.
Clark SL, Tse JY, Fisher DC, et al. Histopathologic spectrum of hypersensitivity
reactions associated with anti-CD52 therapy (alemtuzumab). J Cutan Pathol.
2016;43(11):989-993. doi:10.1111/cup.12800.
Ngu S, Shaffrali F. A case of severe drug reaction secondary to alemtuzumab with
successful re-exposure. Clin Exp Dermatol. 2017;42(8):925-926.
https://t.me/medicina_free
doi:10.1111/ced.13230.
Willis MD, Harding KE, Pickersgill TP, et al. Alemtuzumab for multiple sclerosis:
long term follow-up in a multi-centre cohort. Mult Scler. 2016;22(9):1215-1223.
doi:10.1177/1352458515614092.
Ghodasara R, Smith S, Mosley M. Serious adverse events (SAE), autoimmunity
(AI), and infections following alemtuzumab (ALE) therapy in a large, high
disability, treatment-refractory MS clinic cohort. ECTRIMS Online Libr. 2016.
Available at https://onlinelibrary.ectrims-
congress.eu/ectrims/2016/32nd/145865/samuel.f.hunter.serious.adverse.events.2
8sae29.autoimmunity.28ai29.and.infections.html. Accessed October 8, 2018.
Zimmermann J, Buhl T, Müller M. Alopecia universalis following alemtuzumab
treatment in multiple sclerosis: a barely recognized manifestation of secondary
autoimmunity—report of a case and review of the literature. Front Neurol.
2017;8. doi:10.3389/fneur.2017.00569.
CAMMS223 Trial Investigators , Coles AJ, Compston DA, Selmaj KW, et al.
Alemtuzumab versus interferon beta-1a in early multiple sclerosis. N Engl J
Med. 2008;359(17):1786-1801. doi:10.1056/NEJMoa0802670.
Lambert C, Dubois B, Dive D, et al. Management of immune thrombocytopenia in
multiple sclerosis patients treated with alemtuzumab: a Belgian consensus. Acta
Neurol Belg. 2018;118(1):7-11. doi:10.1007/s13760-018-0882-3.
Cuker A, Coles AJ, Sullivan H, et al. A distinctive form of immune
thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of
relapsing-remitting multiple sclerosis. Blood. 2011;118(24):6299-6305.
doi:10.1182/blood-2011-08-371138.
Cuker A, Stasi R, Palmer J, Oyuela P, Margolin D, Bass A. Successful detection
and management of immune thrombocytopenia in alemtuzumab-treated patients
with active relapsing-remitting multiple sclerosis (P2.198). Neurology.
2014;82(suppl 10). Available at
http://n.neurology.org/content/82/10_Supplement/P2.198.abstract.
Lemtrada FDA Prescribing Information; 2014. Avaialble at
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103948s5139lbl.pdf
.
Pace AA, Zajicek JP. Melanoma following treatment with alemtuzumab for
multiple sclerosis. Eur J Neurol. 2009;16(4):e70-e71. doi:10.1111/j.1468-
1331.2009.02552.x.
Fiegl M, Gastl G, Hopfinger G, et al. Alemtuzumab in chronic lymphocytic
leukaemia, other lymphoproliferative disease and autoimmune disorders. Memo.
2008;1(4):211-222. doi:10.1007/s12254-008-0064-8.
FDA Approves Lemtrada
TM
(alemtuzumab) for Relapsing MS – UPDATE. National
Multiple Sclerosis Society. http://www.nationalmssociety.org/About-the-
Society/News/FDA-Approves-LemtradaTM-(alemtuzumab)-for-Relapsing.
Accessed November 12, 2018.
Davenport RJ, Munday JR. Alpha4-integrin antagonism–an effective approach for
the treatment of inflammatory diseases? Drug Discov Today. 2007;12(13–
14):569-576. doi:10.1016/j.drudis.2007.05.001.
Phillips JT, O’Connor PW, Havrdova E, et al. Infusion-related hypersensitivity
reactions during natalizumab treatment. Neurology. 2006;67(9):1717-1718.
doi:10.1212/01.wnl.0000242629.66372.33.
https://t.me/medicina_free
Krumbholz M, Pellkofer H, Gold R, Hoffmann LA, Hohlfeld R, Kümpfel T.
Delayed allergic reaction to natalizumab associated with early formation of
neutralizing antibodies. Arch Neurol. 2007;64(9):1331-1333.
doi:10.1001/archneur.64.9.1331.
Lapucci C, Gualandi F, Mikulska M, et al. Serum sickness (Like Reaction) in a
patient treated with alemtuzumab for multiple sclerosis: a case report. Mult Scler
Relat Disord. 2018;26:52-54. doi:10.1016/j.msard.2018.09.006.
Piqué-Duran E, Eguía P, García-Vázquez O. Acquired perforating dermatosis
associated with natalizumab. J Am Acad Dermatol. 2013;68(6):e185-e187.
doi:10.1016/j.jaad.2012.11.004.
André MC, Pacheco D, Antunes J, Silva R, Filipe P, Soares de Almeida LM.
Generalized skin drug eruption to natalizumab in a patient with multiple
sclerosis. Dermatol Online J. 2010;16(6). Available at
https://escholarship.org/uc/item/2w71s2mx. Accessed October 31, 2018.
Lambrianides S, Kinnis E, Leonidou E, Pantzaris M. Does natalizumab induce or
aggravate psoriasis? A case study and review of the literature. CRN.
2018;10(3):286-291. doi:10.1159/000492891.
Millán-Pascual J, Turpín-Fenoll L, Del Saz-Saucedo P, Rueda-Medina I, Navarro-
Muñoz S. Psoriasis during natalizumab treatment for multiple sclerosis. J
Neurol. 2012;259(12):2758-2760. doi:10.1007/s00415-012-6713-1.
Clark SJ, Wang Q, Mao-Draayer Y. Switching from natalizumab to fingolimod:
case report and review of literature. J Immunol Clin Res. 2016;3(1):1030.
Vacchiano V, Foschi M, Sabattini L, Scandellari C, Lugaresi A. Arthritic psoriasis
during natalizumab treatment: a case report and review of the literature. Neurol
Sci. 2018;39(1):181-183. doi:10.1007/s10072-017-3112-5.
Panzara MA, Bozic C, Sandrock AW. More on melanoma with transdifferentiation.
N Engl J Med. 2008;359(1):99; author reply 99-100.
doi:10.1056/NEJMc086089.
Sabol RA, Noxon V, Sartor O, et al. Melanoma complicating treatment with
natalizumab for multiple sclerosis: a report from the Southern Network on
Adverse Reactions (SONAR). Cancer Med. 2017;6(7):1541-1551.
doi:10.1002/cam4.1098.
Selewski DT, Shah GV, Segal BM, Rajdev PA, Mukherji SK. Natalizumab
(tysabri). Am J Neuroradiol. 2010;31(9):1588-1590. doi:10.3174/ajnr.A2226.
Bergamaschi R, Montomoli C. Melanoma in multiple sclerosis treated with
natalizumab: causal association or coincidence? Mult Scler. 2009;15(12):1532-
1533. doi:10.1177/1352458509347154.
Ismail A, Kemp J, Sharrack B. Melanoma complicating treatment with natalizumab
(Tysabri) for multiple sclerosis. J Neurol. 2009;256(10):1771-1772.
doi:10.1007/s00415-009-5200-9.
Laroni A, Bedognetti M, Uccelli A, Capello E, Mancardi GL. Association of
melanoma and natalizumab therapy in the Italian MS population: a second case
report. Neurol Sci. 2011;32(1):181-182. doi:10.1007/s10072-010-0427-x.
Mullen JT, Vartanian TK, Atkins MB. Melanoma complicating treatment with
natalizumab for multiple sclerosis. N Engl J Med. 2008;358(6):647-648.
doi:10.1056/NEJMc0706103.
Vavricka BMP, Baumberger P, Russmann S, Kullak-Ublick GA. Diagnosis of
melanoma under concomitant natalizumab therapy. Mult Scler. 2011;17(2):255-
https://t.me/medicina_free
256. doi:10.1177/1352458510389629.
Pharaon M, Tichet M, Lebrun-Frénay C, Tartare-Deckert S, Passeron T. Risk for
nevus transformation and melanoma proliferation and invasion during
natalizumab treatment: four years of dermoscopic follow-up with
immunohistological studies and proliferation and invasion assays. JAMA
Dermatol. 2014;150(8):901-903. doi:10.1001/jamadermatol.2013.9411.
of B-cell therapy. Expert Opin Biol Ther. 2009;9(7):889-895.
doi:10.1517/14712590903018837.
Press Announcements – FDA Approves New Drug to Treat Multiple Sclerosis.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm549325.
htm.
Darwin E, Romanelli P, Lev-Tov H. Ocrelizumab-induced psoriasiform dermatitis
in a patient with multiple sclerosis. Dermatol Online J. 2018;24(7),
pii:13030/qt220859qb.
Granqvist M, Boremalm M, Poorghobad A, et al. Comparative effectiveness of
rituximab and other initial treatment choices for multiple sclerosis. JAMA
Neurol. 2018;75(3):320-327. doi:10.1001/jamaneurol.2017.4011.
FDA. RITUXAN (Rituximab). Genentech Package Insert; 2010. Available at
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103705s5311lbl.pdf
.
Didona D, Paolino G, Garcovich S, Caro RDC, Didona B. Successful use of
etanercept in a case of toxic epidermal necrolysis induced by rituximab. J Eur
Acad Dermatol Venereol. 2016;30(10):e83-e84. doi:10.1111/jdv.13330.
Lowndes S, Darby A, Mead G, Lister A. Stevens–Johnson syndrome after
treatment with rituximab. Ann Oncol. 2002;13(12):1948-1950.
doi:10.1093/annonc/mdf350.
Henning JS, Firoz BF. Rituxan is not associated with Stevens Johnson syndrome.
Ann Oncol. 2011;22(6):1463-1464. doi:10.1093/annonc/mdr254.
Fallon MJ, Heck JN. Fatal Stevens–Johnson syndrome/toxic epidermal necrolysis
induced by allopurinol–rituximab–bendamustine therapy. J Oncol Pharm Pract.
2015;21(5):388-392. doi:10.1177/1078155214533368.
Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of
bendamustine plus rituximab in patients with relapsed indolent B-cell and
mantle cell non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26(27):4473-4479.
doi:10.1200/JCO.2008.17.0001.
Ureshino H, Ando T, Kojima K, et al. Rituximab-containing chemotherapy (R-
CHOP)-induced kaposi’s sarcoma in an HIV-negative patient with diffuse large
B cell lymphoma. Intern Med. 2015;54(24):3205-3208.
doi:10.2169/internalmedicine.54.5103.
Jerdan K, Brownell J, Singh M, Braniecki M, Chan L. A case report of iatrogenic
cutaneous Kaposi sarcoma due to rituximab therapy for thrombotic
thrombocytopenic purpura. Acta Oncol. 2017;56(1):111-113.
doi:10.1080/0284186X.2016.1253867.
Périer A, Savey L, Marcelin AG, Serve P, Saadoun D, Barete S. Brief report: de
novo human herpesvirus 8 tumors induced by rituximab in autoimmune or
inflammatory systemic diseases. Arthritis Rheumatol. 2017;69(11):2241-2246.
doi:10.1002/art.40217.
https://t.me/medicina_free
Billon E, Stoppa AM, Mescam L, et al. Reversible rituximab-induced rectal
Kaposi’s sarcoma misdiagnosed as ulcerative colitis in a patient with HIVnegative follicular lymphoma. Clin Sarcoma Res. 2018;8(1):11.
doi:10.1186/s13569-018-0097-7.
Kandula P, Kouides PA. Rituximab-induced leukocytoclastic vasculitis: a case
report. Arch Dermatol. 2006;142(2):246-247. doi:10.1001/archderm.142.2.246.
Dereure O, Navarro R, Rossi JF, Guilhou JJ. Rituximab-induced vasculitis.
Dermatology (Basel). 2001;203(1):83-84. doi:10.1159/000051713.
D’Arcy CA, Mannik M. Serum sickness secondary to treatment with the murine–
human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum.
2001;44(7):1717-1718. doi:10.1002/1529-0131(200107)44:7<1717::AIDART299>3.0.CO;2-C.
Herishanu Y. Rituximab-induced serum sickness. Am J Hematol. 2002;70(4):329.
doi:10.1002/ajh.10127.
Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H. Teriflunomide and
its mechanism of action in multiple sclerosis. Drugs. 2014;74(6):659-674.
doi:10.1007/s40265-014-0212-x.
Drug Approval Package: Arava (Leflunomide Tablet) NDA# 20905. U.S. Food and
Drug Administration; 1998. Available at
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20905_arava.cfm.
Comi G, Freedman MS, Kappos L, et al. Pooled safety and tolerability data from
four placebo-controlled teriflunomide studies and extensions. Mult Scler Relat
Disord. 2016;5:97-104. doi:10.1016/j.msard.2015.11.006.
FDA Approves First Oral Drug to Reduce MS Relapses; 2010. Available at
https://www.prnewswire.comfda-approves-first-oral-drug-to-reduce-msrelapses-103518384.
Groves A, Kihara Y, Chun J. Fingolimod: direct CNS effects of sphingosine 1-
phosphate (S1P) receptor modulation and implications in multiple sclerosis
therapy. J Neurol Sci. 2013;328(1):9-18. doi:10.1016/j.jns.2013.02.011.
Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and
peripheral lymphoid organs is dependent on S1P receptor 1. Nature.
2004;427(6972):355-360. doi:10.1038/nature02284.
Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive
multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebocontrolled trial. Lancet. 2016;387(10023):1075-1084. doi:10.1016/S01406736(15)01314-8.
Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in
patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a doubleblind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol.
2014;13(6):545-556. doi:10.1016/S1474-4422(14)70049-3.
Mahajan KR, Ko JS, Tetzlaff MT, Hudgens CW, Billings SD, Cohen JA. Merkel
cell carcinoma with fingolimod treatment for multiple sclerosis: a case report.
Mult Scler Relat Disord. 2017;17:12-14. doi:10.1016/j.msard.2017.06.004.
Calvi A, Riz MD, Lecchi E, et al. Merkel cell carcinoma in a patient with relapsing-
remitting multiple sclerosis treated with fingolimod. J Neurol Sci.
2017;381:296-297. doi:10.1016/j.jns.2017.09.003.
Beadnall HN, Gill AJ, Riminton S, Barnett MH. Virus-related Merkel cell
carcinoma complicating fingolimod treatment for multiple sclerosis. Neurology.
https://t.me/medicina_free
2016;87(24):2595-2597. doi:10.1212/WNL.0000000000003434.
FDA. Gilenya (Fingolimod) Prescribing Information; 2018. Available at
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022527s024lbl.pdf.
Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon
for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-415.
doi:10.1056/NEJMoa0907839.
Kappos L, Radue E-W, O’Connor P, et al. A placebo-controlled trial of oral
fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401.
doi:10.1056/NEJMoa0909494.
Comi G, O’Connor P, Montalban X, et al. Phase II study of oral fingolimod
(FTY720) in multiple sclerosis: 3-year results. Mult Scler. 2010;16(2):197-207.
doi:10.1177/1352458509357065.
Killestein J, Leurs CE, Hoogervorst ELJ, et al. Five cases of malignant melanoma
during fingolimod treatment in Dutch patients with MS. Neurology.
2017;89(9):970-972. doi:10.1212/WNL.0000000000004293.
Conzett KB, Kolm I, Jelcic I, et al. Melanoma occurring during treatment with
fingolimod for multiple sclerosis: a case report. Arch Dermatol.
2011;147(8):991-992. doi:10.1001/archdermatol.2011.212.
Robinson CL, Guo M. Fingolimod (gilenya) and melanoma. BMJ Case Rep.
2016;2016. doi:10.1136/bcr-2016-217885. pii:bcr2016217885.
Haebich G, Mughal A, Tofazzal N. Superficial spreading malignant melanoma in a
patient on fingolimod therapy for multiple sclerosis. Clin Exp Dermatol.
2016;41(4):433-434. doi:10.1111/ced.12770.
Tay KH, Liu X, Chi M, et al. Involvement of vacuolar H(+)-ATPase in killing of
human melanoma cells by the sphingosine kinase analogue FTY720. Pigment
Cell Melanoma Res. 2015;28(2):171-183. doi:10.1111/pcmr.12326.
Ishitsuka A, Fujine E, Mizutani Y, et al. FTY720 and cisplatin synergistically
induce the death of cisplatin-resistant melanoma cells through the
downregulation of the PI3K pathway and the decrease in epidermal growth
factor receptor expression. Int J Mol Med. 2014;34(4):1169-1174.
doi:10.3892/ijmm.2014.1882.
Marrie RA, Patten SB, Tremlett H, Wolfson C, Leung S, Fisk JD. Increased
incidence and prevalence of psoriasis in multiple sclerosis. Mult Scler Relat
Disord. 2017;13:81-86. doi:10.1016/j.msard.2017.02.012.
Egeberg A, Mallbris L, Gislason GH, Skov L, Hansen PR. Risk of multiple
sclerosis in patients with psoriasis: a Danish nationwide cohort study. J Invest
Dermatol. 2016;136(1):93-98. doi:10.1038/JID.2015.350.
Guido N, Cices A, Ibler E, et al. Multiple sclerosis association with psoriasis: a
large U.S. population, single centre, retrospective cross-sectional study. J Eur
Acad Dermatol Venereol. 2017;31(9):e397-e398. doi:10.1111/jdv.14205.
Langer-Gould A, Albers K, Van Den Eeden S, Nelson L. Autoimmune diseases
prior to the diagnosis of multiple sclerosis: a population-based case-control
study. Mult Scler. 2010;16(7):855-861. doi:10.1177/1352458510369146.
Edwards LJ, Constantinescu CS. A prospective study of conditions associated with
multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple
sclerosis clinic. Mult Scler. 2004;10(5):575-581.
doi:10.1191/1352458504ms1087oa.
https://t.me/medicina_free
Ramagopalan SV, Dyment DA, Valdar W, et al. Autoimmune disease in families
with multiple sclerosis: a population-based study. Lancet Neurol. 2007;6(7):604-
610. doi:10.1016/S1474-4422(07)70132-1.
Kwok T, Loo WJ, Guenther L. Psoriasis and multiple sclerosis: is there a link? J
Cutan Med Surg. 2010;14(4):151-155. doi:10.2310/7750.2010.09063.
Munschauer FE, Kinkel RP. Managing side effects of interferon-beta in patients
with relapsing-remitting multiple sclerosis. Clin Ther. 1997;19(5):883-893.
doi:10.1016/S0149-2918(97)80042-2.
Hong J, Bernstein D. A review of drugs that induce or exacerbate psoriasis.
Psoriasis Forum. 2012;18a(1):2-11. doi:10.1177/247553031218a00101.
Lozeron P, Denier C, Lacroix C, Adams D. Long-term course of demyelinating
neuropathies occurring during tumor necrosis factor-α–blocker therapy. Arch
Neurol. 2009;66(4):490-497. doi:10.1001/archneurol.2009.11.
Tristano AG. Neurological adverse events associated with anti-tumor necrosis
factor alpha treatment. J Neurol. 2010;257(9):1421-1431. doi:10.1007/s00415010-5591-7.
Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-
tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis
Rheum. 2001;44(12):2862-2869.
Gomez-Gallego M, Meca-Lallana J, Fernandez-Barreiro A. Multiple sclerosis onset
during etanercept treatment. Eur Neurol. 2008;59(1–2):91-93.
doi:10.1159/000109576.
Cruz Fernández-Espartero M, Pérez-Zafrilla B, Naranjo A, et al. Demyelinating
disease in patients treated with TNF antagonists in rheumatology: data from
BIOBADASER, a pharmacovigilance database, and a systematic review. Semin
Arthritis Rheum. 2011;41(3):524-533. doi:10.1016/j.semarthrit.2011.05.003.
Kemanetzoglou E, Andreadou E. CNS demyelination with TNF-α blockers. Curr
Neurol Neurosci Rep. 2017;17(4):36. doi:10.1007/s11910-017-0742-1.
Kay J, Fleischmann R, Keystone E, et al. Golimumab 3-year safety update: an
analysis of pooled data from the long-term extensions of randomised, doubleblind, placebo-controlled trials conducted in patients with rheumatoid arthritis,
psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis. 2015;74(3):538-
546. doi:10.1136/annrheumdis-2013-204195.
Caminero A, Comabella M, Montalban X. Tumor necrosis factor alpha (TNF-α),
anti-TNF-α and demyelination revisited: an ongoing story. J Neuroimmunol.
2011;234(1):1-6. doi:10.1016/j.jneuroim.2011.03.004.
Kaushik SB, Lebwohl MG. CME part I psoriasis: which therapy for which patient
psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol.
2019;80(1):27-40. doi:10.1016/j.jaad.2018.06.057.
Neumann JW, Ziegler DK. Therapeutic trial of immunosuppressive agents in
multiple sclerosis. Neurology. 1972;22(12):1268-1271.
Currier RD, Haerer AF, Meydrech EF. Low dose oral methotrexate treatment of
multiple sclerosis: a pilot study. J Neurol Neurosurg Psychiatry.
1993;56(11):1217-1218. doi:10.1136/jnnp.56.11.1217.
Ashtari F, Savoj MR. Effects of low dose methotrexate on relapsing-remitting
multiple sclerosis in comparison to Interferon β-1α: a randomized controlled
trial. J Res Med Sci. 2011;16(4):457-462.
https://t.me/medicina_free
Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral
methotrexate reduces the rate of progression in chronic progressive multiple
sclerosis. Ann Neurol. 1995;37(1):30-40. doi:10.1002/ana.410370108.
Zhao GJ, Li DKB, Wolinsky JS, et al. Clinical and magnetic resonance imaging
changes correlate in a clinical trial monitoring cyclosporine therapy for multiple
sclerosis. J Neuroimaging. 1997;7(1):1-7. doi:10.1111/jon1997711.
Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper
LH. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody,
ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II,
double-blind, placebo-controlled, randomised, dose-ranging study. Lancet
Neurol. 2008;7(9):796-804. doi:10.1016/S1474-4422(08)70173-X.
Chang S, Chambers CJ, Liu FT, Armstrong AW. Successful treatment of psoriasis
with ustekinumab in patients with multiple sclerosis. Dermatol Online J.
2015;21(7). Available at https://escholarship.org/uc/item/3bs971cr. Accessed
November 8, 2018.
Havrdová E, Belova A, Goloborodko A, et al. Activity of secukinumab, an anti-IL-
17A antibody, on brain lesions in RRMS: results from a randomized, proof-ofconcept study. J Neurol. 2016;263(7):1287-1295. doi:10.1007/s00415-0168128-x.
Goldacre MJ, Seagroatt V, Yeates D, Acheson ED. Skin cancer in people with
multiple sclerosis: a record linkage study. J Epidemiol Community Health.
2004;58(2):142-144. doi:10.1136/jech.58.2.142.
Lebrun C, Vermersch P, Brassat D, et al. Cancer and multiple sclerosis in the era of
disease-modifying treatments. J Neurol. 2011;258(7):1304-1311.
doi:10.1007/s00415-011-5929-9.
Lafaille P, Benedetto A. Fillers: contraindications, side effects and precautions. J
Cutan Aesthet Surg. 2010;3(1):16-19. doi:10.4103/0974-2077.63222.
Laser Hair Removal. Herron Dermatology & Laser. Available at
https://www.herrondermatology.com/cosmetic/laser-hair-removal/. Accessed
November 12, 2018.
https://t.me/medicina_free
C H A P T E R 1 0
Endocrine Disorders in
Multiple Sclerosis
Tiffany Yeh Michele Yeung Dorothy A. Fink
Introduction
Multiple sclerosis (MS) is largely thought to be an
inflammatory autoimmune disease; however, there is
significant cross talk between the endocrine and immune
systems leading to observations of certain endocrine
abnormalities, such as vitamin D deficiency potentially
modulating MS risk and relapse rates. Additionally, many key
treatments of MS, such as alemtuzumab, glucocorticoids (GC),
and biotin, have a number of effects on the endocrine system,
such as thyroid dysfunction, osteoporosis, hypothalamicpituitary-adrenal (HPA) axis suppression, iatrogenic Cushing
syndrome, and diabetes/metabolic syndrome. Here we provide
an overview of these topics and encourage all clinicians
treating patients with MS in their practice to be well versed in
identifying and treating endocrine comorbidities in patients
with MS.
Metabolic Bone Health
The Role of Vitamin D Supplementation in
MS
Expression of both vitamin D receptors and the rate-limiting
enzyme for vitamin D synthesis, 1-alpha-hydroxylase, has
been reported in most immune cells. 1 The suggestion that
vitamin D potentially can have immunomodulatory effects in
https://t.me/medicina_free
Соседние файлы в папке Библиотека им академика М.И. Перельмана